Nature Biotechnology - Defining a longevity biotechnology company

Recent patents relating to devices and methods for the improvement of nanopore sequencing systems.

Improving target selectivity and defining cell phenotypes may improve the odds of finding therapies for fibrosis.

Recollections from an extraordinary 19-year journey guiding a tiny startup with an unproven therapeutic modality into a mature drug company with marketed products and >1,600 employees in nearly 20 countries provide lessons for those seeking to create the culture and values that are core to biotech success.

A team of researchers from Michigan State University's College of Veterinary Medicine has made a discovery that may have implications for therapeutic gene editing strategies, cancer diagnostics and therapies and other advancements in biotechnology.

Lars Larson and I discuss the future of American biotechnology.

Nature Biotechnology - Chan Zuckerberg hubs multiply

Nature Biotechnology - mRNA made in Africa

These innovators are using technology to understand the body at the smallest scale, to find new ways to attack cancer, and to try to cure Duchenne muscular dystrophy.

It's good that we are not our ancestors. An essay by Niko McCarty. Codon is a biotech newsletter about CRISPR, genetic engineering, and science frontiers.

The Securities and Exchange commission is seeking documents related to the November firing of Foxo Technologies' CEO.

Nature Biotechnology - First Rounders: Ingmar Hoerr

Redesigning mRNA with chemo-topological strategies improves its stability and translation efficiency, paving the way for more effective mRNA therapeutics.

Nature Biotechnology - Monitoring protein proximity with fluorogens

The White House's Office of Science and Technology Policy (OSTP) report demonstrates that the federal government is not serious about feeding the country or developing a strong bioeconomy. The report contains decades-old unworkable initiatives. Is the Administration moving a 'bold' and 'innovative' agenda or simply focusing on climate initiatives while China advances its bioeconomy?

January Therapeutics, a leading biotechnology company developing targeted medicines for cancer, announced today the appointment of Thomas B. Broudy, PhD, as Chief Executive Officer. Broudy will lead the company's strategic direction and hold responsibility for advancing the company's therapeutic programs to their upcoming milestones—including internal development and external partnerships.

Succinic acid is an important precursor for pharmaceutical and cosmetic products and also serves as a component in biodegradable plastics. It is currently derived mainly from petroleum-based processes. Researchers at the Straubing campus of the Technical University of Munich (TUM) are using the marine bacterium Vibrio natriegens as a biocatalyst. This could permit the production of succinic acid in sustainable…

As biotechnology advances, the risk of accidental or deliberate misuse of biological research like viral engineering is increasing. At the same time, 'open science' practices like the public sharing of research data and protocols are becoming widespread. An article examines how open science practices and the risks of misuse interface and proposes solutions to the problems identified.

As biotechnology advances, the risk of accidental or deliberate misuse of biological research like viral engineering is increasing. At the same time, "open science" practices like the public sharing of research data and protocols are becoming widespread. An article publishing April 14th in the open access journal PLOS Biology by James Smith and Jonas Sandbrink at the University of Oxford, UK, examines how open…

Wouldn't it be nice to grow crops that grew 50 percent more than current varieties? How about a strain of vegetables that were safe from insects without using pesticides? Agricultural biotechnology can do that.